Skip to main content

Biocius Life Sciences Forms after Life Tech's Biotrove Acquisition

NEW YORK (GenomeWeb News) – Biocius Life Sciences said today that it is now an independent operating company after completing its spin out from parent company Biotrove, which was recently acquired by Life Technologies.

Biocius said that it now holds all of the intellectual property related to the RapidFire mass spectrometry platform formerly owned by Biotrove; and that it will employ all former employees of Biotrove's RapidFire business unit.

In November, Life Technologies announced that it would acquire BioTrove for an undisclosed sum to incorporate Biotrove's OpenArray high-throughput gene expression and genotyping system.

At the time, Biotrove said that it would form the Biocius subsidiary to retain the RapidFire business. Life Tech's acquisition of Biotrove was completed yesterday.

Biocius' investors include Catalyst Health Ventures, Excel Venture Management, Fletcher-Spaght, CB Health Ventures, Vox Equity Partners, Echelon Ventures, and BioFrontier Partners.

Biocius, based in Woburn, Mass., said that it will focus its resources on further developing and marketing the RapidFire platform, as well as new research and development projects to facilitate drug discovery for clients and collaborators.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.